RNA Analytical/Quality Articles

1. Personalized mRNA Cancer Immunotherapies: Closing The Biological Knowledge Gap 11/5/2026

   it was a great honor to take Advancing RNA on the road to London to CPI’s/BIA’s/Imperial College London’s RNA Vaccines & Therapeutics Conference to moderate a discussion on personalized cancer immunotherapies. In the following two-part article, I’ll share the advancements needed in two areas — biological knowledge and manufacturing — to ensure we’re capable of meeting patients’ needs in the personalized sector.

2. Antibody–Oligonucleotide Conjugates, Part 4: Regulatory Considerations And Future Directions 10/30/2026

   This last article of the author's series on AOCs reveals regulatory perspective, analytical opportunities, the emergence of molecular quality by design, and the CMC challenges to address with future work.

3. Antibody–Oligonucleotide Conjugates, Part 3: Analytical Control 10/23/2026

   Let's delve into analytical control strategy, OAR/DAR measurement, bioanalytical characterization, stability and formulation, and more.

4. Antibody–Oligonucleotide Conjugates, Part 1: Approaching Your AOC Development Plan 10/9/2026

   The emergence of antibody–oligonucleotide conjugates (AOCs) addresses delivery issues with huge potential. Let's look at how to approach your development plan with molecular architecture, defining the target product profile, and CQAs.

5. Can Engineering The Passenger Strand Improve siRNA Performance? 10/8/2026

   How can we make the passenger strand easier to reject while keeping the siRNA duplex sufficiently stable before it reaches the machinery that activates it?

6. How Should We Measure The True Potency Of RNA Therapeutics? 10/5/2026

   An RNA therapeutic can generate a strong molecular signal without producing the intended biological function. Let's look at how best to predict whether the RNA has completed its task.

7. Engineering RNA Agonists For Systemic Immunity Without Systemic Toxicity 10/1/2026

   Krieg believes the answer lies in a deeper understanding of innate immune biology and the design of RNA/DNA hybrid mimics of viral RNA and DNA that are detected by innate immune receptors.

8. Why RNA–LNP Development Needs Higher-Resolution Analytics In 2027 9/11/2026

   Raising analytical resolution is among the cheapest interventions available. With regulators tightening and capital selective, it is also among the most consequential.

9. What Oligo Manufacturing Risks Are We Underestimating? 9/8/2026

   Earlier this year, I attended the OPT Congress, where I had the great fortune of meeting consultant Marc Lemaitre. I recently sat down with Lemaitre for a follow-up interview to gauge some of the evolutions he’s been watching within the CMC landscape for oligo development. Here, he digs into the shifts in quality he’s noted, pointing out some of the potential pitfalls we may encounter in our manufacturing that could stand to impact the overall quality of our oligos. 

10. Will 2027 See A Meteoric Rise Of Programmable Nanomedicine? 9/2/2026

    The significance of programmable nanomedicines is not simply that nanoparticles can carry more functions. It is that biological information can become part of the control logic.